NOI - Olink Explore HT Proteomic Analysis for Sepsis Biomarker Study

The National Heart, Lung, and Blood Institute (NHLBI) plans to issue a non-competitive, firm-fixed-price purchase order to Psomagen, Inc. for high-throughput proteomic analysis services using the Olink Explore HT platform to support research on inflammatory biomarkers and therapeutic responses in a non-human primate septic shock model. The contractor is responsible for processing plasma samples, executing assays with NGS-based readout to quantify over 5,400 proteins, performing rigorous quality control, and delivering normalized, analysis-ready datasets in a timely manner compatible with existing NHLBI research infrastructure. This acquisition is justified under FAR 6.302-3(a)(2)(ii) as a sole-source procurement due to the unique technical capability of the Olink Explore HT platform, which only Psomagen, Inc. can provide without compromising data comparability and scientific validity. The work will be performed primarily in Rockville, Maryland, with final deliverables submitted to the NHLBI facility in Bethesda, Maryland. The solicitation, identified as 75N98026Q00280, treats the services as commercial items under FAR Part 12 and requires offerors to comply with standard commercial item clauses including 52.212-1 through 52.212-5. Proposals must include a capability statement demonstrating the ability to meet the technical requirements along with a UEI, TIN, business size certification, product descriptions, pricing, and F.O.B. terms. No formal evaluation hierarchy, weights, or risk ratings are specified; award is contingent solely on confirmation of technical capability rather than price competition. The response deadline is May 13, 2026, with submissions required electronically via email to the designated contracting officer, Nicholas Capobianco. No set-aside applies, no options or delivery schedules are defined, and no special security, personnel, or packaging requirements are imposed. Payment procedures, invoicing systems, and contract value figures are not specified, and no formal inspection criteria beyond technical deliverable acceptance are outlined. All contractual obligations are anchored in commercial practices and the contractor's ability to deliver scientifically valid, analysis-ready proteomic data using the specified platform.